KaNDy’s lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The acquisition will add KaNDy’s menopause drug to Bayer’s portfolio. KaNDy has published results of its NT-814 in P-IIb study that… Read More »Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare Portfolio
Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline. Bayer will pay $425 million up front and potential milestone payments of up to $450 million until launch, followed by… Read More »Bayer adds menopause drug to pipeline with KaNDy acquisition